Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Ampio, Paladin Labs Partner on Zertane Rights

April 10, 2014 10:55 am | News | Comments

Ampio Pharmaceuticals Inc. announced that its subsidiary Vyrix Pharmaceuticals has signed an agreement with Paladin Labs Inc. to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America. Read more...

TOPICS:

Gilead Posts Positive Results for All-Oral Sofosbuvir Regimens

April 10, 2014 10:47 am | News | Comments

Gilead Sciences Inc. announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. Read more...

TOPICS:

AbbVie's New Advanced Parkinson's Treatment Available in Canada

April 10, 2014 10:38 am | News | Comments

AbbVie announced that a new treatment called Duodopa (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Read more...                        

TOPICS:
Advertisement

Hemophilia Drug Maintains Low Bleeding Rates in Children

April 10, 2014 10:34 am | News | Comments

Biogen Idec and Sobi released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate in children with severe hemophilia A. Read more...            

TOPICS:

New Vaccine Hope for Viral Cause of Birth Defects

April 10, 2014 10:25 am | News | Comments

Experts in infection and immunity have made a path-finding discovery that could lead to the development of a vaccine for a health-ravaging virus that affects around 50% of adults in the UK. Read more...              

TOPICS:

Have Millions Been Wasted on Flu Drug?

April 10, 2014 10:11 am | News | Comments

British scientists say there isn’t enough evidence to prove the antiviral drug Tamiflu reduces the spread of flu. New study findings question whether governments worldwide were justified in spending millions on the drug during the 2009 swine flu pandemic. Read more...

TOPICS:

Erytech Expands Tumor Starvation Development Portfolio

April 9, 2014 1:59 pm | News | Comments

Erytech Pharma announced the addition of a new product development candidate, ERY-MET, to the company’s tumor starvation product pipeline. Read more...                             

TOPICS:

Lilly, T1D Exchange Collaborate to Advance Diabetes Care

April 9, 2014 1:54 pm | News | Comments

T1D Exchange and Eli Lilly and Co. announced they have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with type 1 diabetes. Read more...      

TOPICS:
Advertisement

Nektar Reports Positive Preclinical Data for Two Oncology Programs

April 9, 2014 1:48 pm | News | Comments

Nektar Therapeutics announced that positive preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the AACR in San Diego, Calif. Read more...                      

TOPICS:

FDA Wants More Info on Forest’s COPD Drug

April 9, 2014 1:38 pm | News | Comments

Forest Laboratories Inc. and Almirall S.A. announced that they have recently received feedback from the FDA regarding the fixed dose combination of aclidinium and formoterol for treatment of COPD. Read more...            

TOPICS:

Phase 2 Efatutazone Trial Shows Challenge of Matching Treatment to Population

April 9, 2014 1:29 pm | News | Comments

Researchers hope that new work on a Phase 2 trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer will allow them to make better future use of the drug or other drugs in its class. Read more...      

TOPICS:

FDA Stops Halozyme PEGPH20 Pancreatic Cancer Trial

April 9, 2014 1:05 pm | News | Comments

Halozyme Therapeutics Inc. announced that the FDA informed the company Tuesday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer. Read more...

TOPICS:

Faking Fluorescence

April 9, 2014 11:05 am | by Takeharu Nagai, Ph.D., Osaka University, Japan | Articles | Comments

The world’s brightest luminescent protein, a discovery dubbed the “Nano-lantern,” is lighting up the future of in vivo imaging– without the use of external light. This could benefit more advanced applications, such as high-throughput drug screening and single-cell tracking in live animals and plants.

TOPICS:

Immunotherapy Shows Early Promise Against Advanced Melanoma

April 9, 2014 10:45 am | News | Comments

A new type of immunotherapy that directs patients’ immune responses toward tumor cell killing, IMCgp100, was well tolerated and showed efficacy in some patients with advanced melanoma in a Phase 1 clinical trial. Read more...        

TOPICS:

Glucosamine Promotes Longevity in Mice

April 9, 2014 10:35 am | News | Comments

Feeding glucosamine to mice extended their lifespan by almost 10%, reflecting around eight additional years of human lifespan. Moreover, the supplement improved glucose metabolism in elderly mice, indicating that it may provide protection from diabetes. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading